Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Subscribe To Our Newsletter & Stay Updated
